| 13.42 0.13 (0.98%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.68 | 1-year : | 20.66 |
| Resists | First : | 15.14 | Second : | 17.68 |
| Pivot price | 13.42  |
|||
| Supports | First : | 11.43 | Second : | 9.14 |
| MAs | MA(5) : | 13.84 |
MA(20) : | 12.88 |
| MA(100) : | 8.18 |
MA(250) : | 5.8 |
|
| MACD | MACD : | 1 |
Signal : | 1.2 |
| %K %D | K(14,3) : | 57.7 |
D(3) : | 64.9 |
| RSI | RSI(14): 61.6 |
|||
| 52-week | High : | 15.14 | Low : | 2.59 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AMLX ] has closed above bottom band by 49.9%. Bollinger Bands are 43.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 25 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 13.73 - 13.8 | 13.8 - 13.86 |
| Low: | 13.06 - 13.13 | 13.13 - 13.2 |
| Close: | 13.31 - 13.42 | 13.42 - 13.53 |
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Sun, 05 Oct 2025
Have Amylyx Pharmaceuticals Insiders Been Selling Stock? - simplywall.st
Fri, 03 Oct 2025
B of A Securities Maintains Amylyx Pharmaceuticals (AMLX) Buy Recommendation - Nasdaq
Thu, 02 Oct 2025
Amylyx Pharmaceuticals Executives Cash In on Major Stock Sales! - TipRanks
Mon, 29 Sep 2025
Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 52-Week High - What's Next? - MarketBeat
Sun, 21 Sep 2025
Amylyx Pharmaceuticals (AMLX) Raises $175 Million in Equity Offering Are Growth Priorities Being Reassessed? - Sahm
Mon, 15 Sep 2025
Guggenheim raises Amylyx Pharmaceuticals stock price target on PBH potential - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 107 (M) |
| Held by Insiders | 5.862e+007 (%) |
| Held by Institutions | 7.8 (%) |
| Shares Short | 7,430 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.963e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 79 % |
| Return on Assets (ttm) | 106.4 % |
| Return on Equity (ttm) | -46.8 % |
| Qtrly Rev. Growth | -249000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 5.85 |
| EBITDA (p.s.) | -1.18 |
| Qtrly Earnings Growth | -2.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -166 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 2.29 |
| Price to Cash Flow | -2.36 |
| Dividend | 0 |
| Forward Dividend | 8.77e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|